The PTO refused to grant Charles Fote’s patent covering a Broker-Mediated Payment System after concluding that the claims lacked eligibility.  On appeal, Fote argued otherwise — especially considering the PTO’s new (limited) approach to eligibility examination. 

A decision from the Boards of Appeal at the European Patent Office has revoked the claim of the Broad Institute to general patents on CRISPR/Cas9 gene editing technology, strengthening the position of its opponent UC Berkeley in Europe.

In a series of IPR proceedings between Petitioner Adobe Inc. and Patent Owner RAH Color Technologies LLC, the Patent Trial and Appeal Board declined to extend attorney work product protection to deposition questions seeking the “underlying factual basis” for an expert’s testimony and compelled the expert to provide written answers to particular questions. 

The Federal Circuit and the patent world continue to grapple with the court’s decision in Arthrex v. Smith & Nephew.  The parties’ invited responses are due to the court as part of the court’s process to grant or deny rehearing or en banc rehearing in Arthrex.

VirnetX notes that the case ‘has been pending for more than a decade, has been the subject of three trials and two appeals,’ and that ‘in each trial, the jury found against Apple’ in addition to the district court finding that Apple engaged in gamesmanship.